Diabetes & Endocrinology – Page 30

The Protective Effects of High-Intensity Interval Training on Cardiovascular, Neurological, and Metabolic Health

By MedXY 08/18/2025

High-intensity interval training (HIIT) offers significant protective benefits for the cardiovascular, neurological, and metabolic systems, promoting overall health and disease prevention.

Cardiology Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Recent Advances in High-Intensity Interval Training: Cardiovascular, Metabolic, Diabetes, and Neuroprotective Effects

By MedXY 08/18/2025

This review synthesizes recent evidence on the benefits of high-intensity interval training (HIIT) on cardiovascular health, diabetes management, metabolic function, and neuroprotection, highlighting mechanistic insights and clinical implications.

Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Top 10 Weight Loss Pitfalls and How to Avoid Them: A Science-Based Guide

By MedXY 08/17/2025

Uncover the ten most common weight loss misconceptions and pitfalls, and learn scientifically grounded practices to achieve sustainable, healthy fat loss.

Clinical Updates Diabetes & Endocrinology news Specialties

Five Oral Obesity Drugs That Could Rival Eli Lilly’s Orforglipron in the Weight Loss Arena

By MedXY 08/17/2025

Eli Lilly's oral GLP-1 drug orforglipron marks a milestone in obesity treatment, yet competition from novel oral therapies by Novo Nordisk, Viking Therapeutics, Roche, Terns Pharmaceuticals, and Rhythm Pharmaceuticals is intensifying, promising diverse mechanisms and potential market shifts.

Diabetes & Endocrinology news Specialties

Debunking Weight Loss Myths: Avoid These Pitfalls for More Effective and Healthy Weight Loss

By MedXY 08/17/2025

This article explores common weight loss misconceptions, offering scientific insights and strategies for safe and sustainable fat loss.

Diabetes & Endocrinology news Specialties

Debunking 7 Common Weight Loss Myths: What You Need to Know for Healthy Fat Loss

By MedXY 08/17/2025

Explore seven prevalent misconceptions about weight loss—from ignoring obesity as a disease to the dangers of rapid slimming—founded on medical evidence and expert advice to guide safe and effective weight management.

Cardiology Diabetes & Endocrinology news Specialties

Tirzepatide’s Role in Obesity-Related HFpEF: Influence of BMI, Central Adiposity, and Weight Loss from the SUMMIT Trial

By MedXY 08/17/2025

Tirzepatide reduces heart failure risk in obese HFpEF patients regardless of BMI or central adiposity, with greater benefits on exercise capacity and symptom scores associated with higher BMI and weight loss.

Clinical Updates Diabetes & Endocrinology Neurology news Specialties

Obicetrapib Shows Promise in Slowing Alzheimer’s Disease Progression Through Lipid Modulation

By MedXY 08/17/2025

Obicetrapib, a CETP inhibitor, significantly slowed Alzheimer’s disease biomarker progression over 12 months and improved p-tau217 levels in APOE4 carriers while also benefiting lipid profiles in cardiovascular disease patients.

Clinical Updates Diabetes & Endocrinology news Ophthalmology Specialties

Long-Term Metformin Use Linked to Reduced Risk of Age-Related Macular Degeneration in Diabetic Patients

By MedXY 08/17/2025

A large retrospective study found that diabetic patients using metformin for at least five consecutive years have a significantly lower risk of developing age-related macular degeneration, especially the dry type.

Diabetes & Endocrinology news Specialties

Synergistic Effects of Metformin and Moderate FODMAP Diet in Improving Postprandial Glycemia and Gut Health in Prediabetes

By MedXY 08/17/2025

Combining metformin with a moderate FODMAP diet improves postprandial glucose control, enhances GLP-1 secretion, increases butyrate-producing gut bacteria, and reduces inflammation without worsening gastrointestinal side effects in prediabetic patients.

Cardiology Diabetes & Endocrinology news Specialties

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial

By MedXY 08/17/2025

The SOUL trial demonstrates that oral semaglutide significantly reduces major cardiovascular events in type 2 diabetes patients, independently of concurrent SGLT2 inhibitor use, with a favorable safety profile.

Cardiology Diabetes & Endocrinology Nephrology Specialties

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial

By MedXY 08/16/2025

The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.

Clinical Updates Diabetes & Endocrinology news Specialties Urology

SGLT2 Inhibitors Lower Mortality Risk Post-UTI in Diabetes

By MedXY 08/14/2025

Recent research indicates that patients with type 2 diabetes who use SGLT2 inhibitors after a urinary tract infection have a lower mortality risk compared to those using DPP-4 inhibitors.

Cardiology Diabetes & Endocrinology news Specialties

The Long-Term Legacy of Atorvastatin: Insights from the 20-Year ASCOT-Legacy Follow-Up

By MedXY 08/13/2025

The ASCOT-Legacy study shows atorvastatin significantly reduces long-term cardiovascular events and deaths over 20 years in hypertensive patients, supporting early statin initiation for cardiovascular prevention.

Clinical Updates Diabetes & Endocrinology Gastroenterology news Specialties

Dapagliflozin Shows Promising Benefits for Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Landmark Multicentre Trial

By MedXY 08/13/2025

Dapagliflozin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis outcomes without increasing adverse events, according to a rigorous 48-week randomized trial.

Diabetes & Endocrinology Nephrology news Specialties

Exploring Combined Finerenone and Empagliflozin Therapy in CKD and Type 2 Diabetes: Baseline Insights from the CONFIDENCE Trial

By MedXY 08/13/2025

The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818 diverse participants.

Diabetes & Endocrinology news Specialties

Improving Patient Safety: The Role of Deprescribing Diabetes Medication in Older Adults

By MedXY 08/11/2025

This study examines the effectiveness of physician academic detailing combined with previsit patient activation to increase diabetes medication deprescribing amongst older adults, aiming to reduce hypoglycemia-related complications.

Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Exploring Auricular Acupressure: A Promising Complementary Intervention for Older Adults with Type 2 Diabetes

By MedXY 08/11/2025

A recent study investigates auricular acupressure's effects on glycemic markers, stress, and sleep quality in older adults with Type 2 diabetes, revealing promising outcomes and potential for nursing interventions.

Diabetes & Endocrinology Neurology news Specialties

Diabetic Peripheral Neuropathy as a Predictor of Lacunar Stroke in Diabetes Patients

By MedXY 08/11/2025

A study reveals diabetic peripheral neuropathy (DPN) significantly associates with cerebral small-vessel disease (SVD), indicating a predictive role for lacunar stroke in diabetic patients and highlighting opportunities for early intervention.

Clinical Updates Diabetes & Endocrinology news OB/GYN & Women's Health Specialties

Optimal Exercise Order for Glycemic Control in Postmenopausal Women with Type 2 Diabetes

By MedXY 08/11/2025

This article reviews a study examining the effects of aerobic versus resistance exercise execution order on glycemia, blood pressure, and heart rate variability in postmenopausal women with type 2 diabetes, emphasizing clinical implications.